REG-argenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx reported first quarter revenue of $1.3 billion, up 63% year-over-year, with diluted EPS rising to $5.52 from $2.58 in the prior year period. The company announced a leadership transition, appointing Karen Massey as Chief Executive Officer effective May 6, while Tim Van Hauwermeiren moves to non-executive Chair.
Key figures
- Eps
- 5.52
- Revenue
- 1298000000
- Guidance
- PDUFA date for seronegative gMG is May 10, 2026; topline myositis data expected Q3 2026
- Revenue Yoy
- 63%
- Total liquidity
- 4900000000
- Operating profit
- 394000000
- Cash and equivalents
- 4300000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.